Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...